Changing the Face of Cardiovascular Trial Participation: Moving Beyond Middle-Aged White Guys per David D. Waters, MD

Obtenir text complet

Atorvastatin Has a Dose‐Dependent Beneficial Effect on Kidney Function and Associated Cardiovascular Outcomes: Post Hoc Analysis of 6 Double‐Blind Randomized Controlled Trials per Liffert Vogt, Sripal Bangalore, Rana Fayyad, Shari Melamed, G. Kees Hovingh, David A. DeMicco, David D. Waters

Obtenir text complet

The association between lipid levels and leukocyte count: A cross-sectional and longitudinal analysis of three large cohorts per Sonia Sawant, Bradley Tucker, Praween Senanayake, David D. Waters, Sanjay Patel, Kerry-Anne Rye, Kwok Leung Ong, Blake J. Cochran

Obtenir text complet

Relationship of High‐Density Lipoprotein Cholesterol With Renal Function in Patients Treated With Atorvastatin per Kwok Leung Ong, David D. Waters, Rana Fayyad, Liffert Vogt, Shari Melamed, David A. DeMicco, Kerry‐Anne Rye, Philip J. Barter

Obtenir text complet

Prediction of cardiovascular events in statin-treated stable coronary patients of the treating to new targets randomized controlled trial by lipid and non-lipid biomarkers. per Benoit J Arsenault, Philip Barter, David A DeMicco, Weihang Bao, Gregory M Preston, John C LaRosa, Scott M Grundy, Prakash Deedwania, Heiner Greten, Nanette K Wenger, James Shepherd, David D Waters, John J P Kastelein, Treating to New Targets (TNT) Investigators

Obtenir text complet